Literature DB >> 15969209

[Effects of peroxisome proliferator-activated receptor gamma ligands on monocrotaline-induced pulmonary hypertension in rats].

Yasushi Matsuda1, Yasushi Hoshikawa, Shingo Ameshima, Satoshi Suzuki, Yoshinori Okada, Toshiharu Tabata, Takafumi Sugawara, Yuuji Matsumura, Takashi Kondo.   

Abstract

Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear hormone receptor superfamily, which regulates transcription of target genes in a ligand-dependent manner. Ligands for PPARgamma have been shown to attenuate proliferation of vascular smooth muscle cells, and to induce apoptosis in several cell lines in vitro. Since monocrotaline (MCT)-induced pulmonary hypertension in rats is characterized by proliferation of pulmonary vascular smooth muscle cells, we hypothesized that PPARgamma ligands may reduce MCT-induced pulmonary hypertension. To test this hypothesis, we treated MCT-injected rats with pioglitazone and troglitazone, synthetic ligands for PPARgamma, for three weeks and measured pulmonary artery pressure and pulmonary vessel wall thickness. TdT-mediated dUTP-biotin nick end labeling (TUNEL) and immunostaining for proliferating cell nuclear antigen (PCNA) were utilized to assess apoptosis and cell proliferation in the pulmonary arterial walls of pioglitazone-treated rats. MCT with pioglitazone or troglitazone treatment significantly reduced pulmonary hypertension and wall thickening of the pulmonary arteries. TUNEL-positive apoptotic cells were not seen in the pulmonary arterial walls of either MCT-injected or control rats with or without pioglitazone. PCNA-positive cells were only seen in the thickened pulmonary arterial walls of MCT rats, but not in the pulmonary arterial walls of controls and of pioglitazone-treated MCT rats. We conclude that PPARgamma ligands reduce MCT-induced pulmonary hypertension and pulmonary vascular wall thickening in rats. Inhibition of MCT-induced cell proliferation in the pulmonary arterial walls may account for this effect

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15969209

Source DB:  PubMed          Journal:  Nihon Kokyuki Gakkai Zasshi        ISSN: 1343-3490


  37 in total

1.  Peroxisome proliferator-activated receptor γ inhibits pulmonary hypertension targeting store-operated calcium entry.

Authors:  Yingfeng Wang; Wenju Lu; Kai Yang; Yan Wang; Jie Zhang; Jing Jia; Xin Yun; Lichun Tian; Yuqin Chen; Qian Jiang; Bo Zhang; Xiuqing Chen; Jian Wang
Journal:  J Mol Med (Berl)       Date:  2014-11-14       Impact factor: 4.599

Review 2.  PPARgamma as a potential therapeutic target in pulmonary hypertension.

Authors:  Roy L Sutliff; Bum-Yong Kang; C Michael Hart
Journal:  Ther Adv Respir Dis       Date:  2010-06       Impact factor: 4.031

3.  Time-dependent PPARγ Modulation of HIF-1α Signaling in Hypoxic Pulmonary Artery Smooth Muscle Cells.

Authors:  Justine I Blum; Kaiser M Bijli; Tamara C Murphy; Jennifer M Kleinhenz; C Michael Hart
Journal:  Am J Med Sci       Date:  2016-04-04       Impact factor: 2.378

Review 4.  Novel strategy for treatment of pulmonary arterial hypertension: enhancement of apoptosis.

Authors:  Jing-bin Huang; Ying-long Liu; Pei-wu Sun; Xiao-dong Lv; Kong Bo; Xiang-ming Fan
Journal:  Lung       Date:  2010-03-06       Impact factor: 2.584

5.  The PPARbeta/delta agonist GW0742 relaxes pulmonary vessels and limits right heart hypertrophy in rats with hypoxia-induced pulmonary hypertension.

Authors:  Louise S Harrington; Laura Moreno; Anna Reed; Stephen J Wort; Béatrice Desvergne; Christopher Garland; Lan Zhao; Jane A Mitchell
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.752

6.  Implication of in vivo circulating fibrocytes ablation in experimental pulmonary hypertension murine model.

Authors:  Vandana S Nikam; Sandeep Nikam; Akyl Sydykov; Katrin Ahlbrecht; Rory E Morty; Werner Seeger; Robert Voswinckel
Journal:  Br J Pharmacol       Date:  2020-04-12       Impact factor: 8.739

7.  Repurposing rosiglitazone, a PPAR-γ agonist and oral antidiabetic, as an inhaled formulation, for the treatment of PAH.

Authors:  Jahidur Rashid; Ahmad Alobaida; Taslim A Al-Hilal; Samia Hammouda; Ivan F McMurtry; Eva Nozik-Grayck; Kurt R Stenmark; Fakhrul Ahsan
Journal:  J Control Release       Date:  2018-04-30       Impact factor: 9.776

Review 8.  Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment.

Authors:  Nicholas K H Khoo; Bruce A Freeman
Journal:  Curr Opin Pharmacol       Date:  2010-01-14       Impact factor: 5.547

9.  The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation.

Authors:  David E Green; Tamara C Murphy; Bum-Yong Kang; Jennifer M Kleinhenz; Cédric Szyndralewiez; Patrick Page; Roy L Sutliff; C Michael Hart
Journal:  Am J Respir Cell Mol Biol       Date:  2012-08-16       Impact factor: 6.914

10.  Sildenafil inhibits hypoxia-induced transient receptor potential canonical protein expression in pulmonary arterial smooth muscle via cGMP-PKG-PPARγ axis.

Authors:  Jian Wang; Kai Yang; Lei Xu; Yi Zhang; Ning Lai; Hua Jiang; Yajie Zhang; Nanshan Zhong; Pixin Ran; Wenju Lu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-08       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.